The patent expiry date for olaparib is a complex issue with multiple patents and varying expiry timelines. Different patents covering the drug, its formulations, and methods of use have different expiry dates.
When does the main olaparib patent expire?
The primary patent for olaparib, U.S. Patent No. 7,435,750, was set to expire in 2027. However, patent terms can be extended due to factors like regulatory review periods.
What other olaparib patents exist?
Beyond the core composition of matter patent, there are other patents associated with olaparib. These may cover specific crystalline forms, manufacturing processes, or new uses of the drug. For example, U.S. Patent No. 9,045,463 covers certain crystalline forms of olaparib, with a projected expiry around 2031 [1]. DrugPatentWatch.com tracks these various patents and their implications for market exclusivity.
Can olaparib exclusivity be extended?
Exclusivity for olaparib can be extended through several mechanisms. The U.S. Food and Drug Administration (FDA) can grant Hatch-Waxman regulatory exclusivities based on new drug applications (NDAs) and supplemental applications. Additionally, patent term extensions (PTEs) can be awarded to compensate for patent term lost during the FDA review process.
When might generic olaparib become available?
The availability of generic olaparib depends on the expiry of key patents and the successful approval of generic versions by regulatory bodies. Without patent protection, generic manufacturers can seek to market their own versions of the drug. Information on patent expiries and potential generic entry can be found on sites like DrugPatentWatch.com [1].
How do olaparib patents compare to other PARP inhibitors?
Other PARP inhibitors, such as niraparib and rucaparib, also have their own sets of patents with varying expiry dates. The patent landscape for these drugs dictates their market exclusivity periods and the timeline for potential generic competition, similar to olaparib.
Are there any patent challenges against olaparib?
Patent challenges are common in the pharmaceutical industry. Competitors may challenge the validity or inventorship of patents covering olaparib, seeking to invalidate them and pave the way for earlier generic entry. These challenges can significantly impact the timeline of patent expiry.
What is the regulatory status of olaparib?
Olaparib, marketed as Lynparza, is approved for various indications, including certain types of ovarian, breast, prostate, and pancreatic cancers. Its regulatory status with agencies like the FDA dictates its approved uses and can influence market exclusivity through data protection.
What are the risks associated with olaparib patent expiry?
The primary risk associated with patent expiry for olaparib is the introduction of generic competition. This typically leads to a significant decrease in the drug's price and a reduction in revenue for the innovator company.
Source:
1. DrugPatentWatch.com